JP2021534769A - デコイポリペプチド - Google Patents

デコイポリペプチド Download PDF

Info

Publication number
JP2021534769A
JP2021534769A JP2021510191A JP2021510191A JP2021534769A JP 2021534769 A JP2021534769 A JP 2021534769A JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021534769 A JP2021534769 A JP 2021534769A
Authority
JP
Japan
Prior art keywords
substitution
variant
decoy polypeptide
decoy
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534769A5 (https=
Inventor
バン ジャネット シム，
ジャウメ ポンス，
Original Assignee
エーエルエックス オンコロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーエルエックス オンコロジー インコーポレイテッド filed Critical エーエルエックス オンコロジー インコーポレイテッド
Publication of JP2021534769A publication Critical patent/JP2021534769A/ja
Publication of JP2021534769A5 publication Critical patent/JP2021534769A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021510191A 2018-08-31 2019-08-29 デコイポリペプチド Pending JP2021534769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725977P 2018-08-31 2018-08-31
US62/725,977 2018-08-31
PCT/US2019/048921 WO2020047326A2 (en) 2018-08-31 2019-08-29 Decoy polypeptides

Publications (2)

Publication Number Publication Date
JP2021534769A true JP2021534769A (ja) 2021-12-16
JP2021534769A5 JP2021534769A5 (https=) 2022-09-06

Family

ID=67997686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510191A Pending JP2021534769A (ja) 2018-08-31 2019-08-29 デコイポリペプチド

Country Status (5)

Country Link
US (1) US20210347848A1 (https=)
EP (1) EP3843772A2 (https=)
JP (1) JP2021534769A (https=)
MA (1) MA53493A (https=)
WO (1) WO2020047326A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN121243368A (zh) * 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
KR20230018475A (ko) * 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2025222106A1 (en) * 2024-04-18 2025-10-23 Aktis Oncology, Inc. Decoy miniproteins, compositions, & methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501896A (ja) * 2012-12-17 2016-01-21 トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療
WO2017027422A1 (en) * 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
JP2017060462A (ja) * 2015-08-07 2017-03-30 アレキソ セラピューティクス インク． Ｓｉｒｐ−アルファ変異体構築物及びその使用
JP2018524282A (ja) * 2015-05-18 2018-08-30 エービー イニチオ バイオセラピューティクス，インク． Ｓｉｒｐポリペプチド組成物および使用の方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US20030118997A1 (en) * 2001-08-10 2003-06-26 Genset, S.A. Human cDNAs and proteins and uses thereof
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2010070047A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
HRP20150553T1 (hr) * 2009-05-15 2015-08-28 University Health Network Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
EP2699596A4 (en) * 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501896A (ja) * 2012-12-17 2016-01-21 トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療
JP2018524282A (ja) * 2015-05-18 2018-08-30 エービー イニチオ バイオセラピューティクス，インク． Ｓｉｒｐポリペプチド組成物および使用の方法
WO2017027422A1 (en) * 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
JP2017060462A (ja) * 2015-08-07 2017-03-30 アレキソ セラピューティクス インク． Ｓｉｒｐ−アルファ変異体構築物及びその使用

Also Published As

Publication number Publication date
EP3843772A2 (en) 2021-07-07
MA53493A (fr) 2021-07-07
WO2020047326A2 (en) 2020-03-05
US20210347848A1 (en) 2021-11-11
WO2020047326A3 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
KR102943539B1 (ko) 인터류킨-2 작용제 및 이의 용도
JP7064234B2 (ja) Ｓｉｒｐポリペプチド組成物および使用の方法
CN108350055B (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
JP2021534769A (ja) デコイポリペプチド
TWI786034B (zh) 靶向afp肽/mhc複合體之構築體及其用途
JP2023531705A (ja) 抗ｃｃｒ８抗体療法：バイオマーカー及び併用療法
JP2022065039A (ja) マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
CN111971304B (zh) 在酸性pH结合至VISTA的抗体
JP2022518925A (ja) 受容体チロシンキナーゼ様オーファン受容体１（ｒｏｒ１）に特異的な抗体およびキメラ抗原受容体
CN121243368A (zh) 用于治疗癌症的组合疗法
TW201902929A (zh) 專一性辨識磷脂肌醇蛋白聚醣3 (glypican 3) 之構築體及其用途
JP2023507110A (ja) Ｉｌｔ３結合剤及びその使用方法
WO2017180713A1 (en) Anti-psma antibodies and use thereof
TW202313094A (zh) 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
TW201708260A (zh) 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途
TW202309088A (zh) 新的穩定抗ｖｉｓｔａ抗體
WO2024193635A1 (en) Sirp variants and uses thereof
TW201827453A (zh) 靶向hiv肽/mhc複合物之構築體及其用途
RU2822366C2 (ru) Химерные антигенные рецепторы и связывающие агенты, нацеленные на dll3
JP2026505058A (ja) Ｂ７－Ｈ３の４Ｉｇアイソフォームに対する選択性を有する抗体およびその使用方法
TW202600601A (zh) Ｔｒｏｐ２特異性抗原結合蛋白與細胞激素之共軛物
WO2026036085A1 (en) Antibodies targeting dll3 and methods of use thereof
TW202600602A (zh) ４－１ｂｂ配體細胞外域的突變蛋白、包含其的融合蛋白及其用途
JP2026500503A (ja) Ｂａｆｆ－ｒおよびｃｄ１９に特異的なキメラ抗原受容体、ならびにその方法および使用
HK40107886A (zh) 抗ccr8抗体疗法：生物标志物和组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213